Abstract: The invention provides isolated AIF and PPIA binding peptides that disrupt PPIA/AIF complex formation and/or activity and prevent the resulting death of myocardial cells and to pharmaceutical compositions thereof. The invention further provides uses of the isolated peptides in methods of preventing myocardial cell death and/or sudden cardiac death in subject.

Abstract: An electronic messaging device includes a receiver configured to receive a message at one of a first operational frequency and second operational frequency. The messaging device can operate using a time synchronous protocol and can receive commands through over-the-internet-programming (OTIP) and over-the-air-programming (OTAP).

Abstract: The present disclosure relates to compounds according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Abstract: The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically, the liposomal composition is used for prevention, or early treatment, of pathogenic infection in the respiratory tract, preferably by nasal or pulmonary administration.

Abstract: Embodiments of the invention relate to stem cells having conditional immune-evasion capabilities, methods of preparing cells and methods for using these stem cells to repair muscle tissue.

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).

Abstract: The present invention relates to compositions and methods for producing, identifying and isolating heart progenitor cells.

Abstract: Provided herein are, inter alia, are methods, compositions and kits for producing populations of myogenic progenitor cells, and compositions comprising the cell populations derived thereof. Also included are methods and compositions for treating or preventing a muscle disease or disorder in a subject (e.g., Duchenne muscular dystrophy (DMD).

Abstract: A network function virtualization (NFV) platform can support virtual network functions (VNFs) whose behavior can change during their lifecycles. For example, a VNF manager of the NFV platform can receive a request to update a condition of a VNF and/or an action to perform upon satisfaction of the condition. Based on the condition and action, the VNF manager can create or store a lifecycle management policy in an extensible lifecycle management model associated with the virtual network function. Based on the lifecycle management policy, the VNF manager can monitor the virtual network function to detect satisfaction of the condition and, in response to detecting satisfaction of the condition, the VNF manager can perform the action associated with the lifecycle management policy.

Abstract: The disclosure relates to a system and method for automatic sorting of natural intestines/casings for use in the production of food products, and especially as casings for sausages. A partly hollow feeding mandrel is configured to hold an intestine such that the intestine surrounds the feeding mandrel. The feeding mandrel includes a measuring area configured to transport water through a hollow part of the feeding mandrel through punctures in a surface of the measuring area, and into a cavity of the surrounding intestine. A vision device obtains images of the intestine, and a processor processes the images to sort the natural intestines or casings.

Abstract: A network function virtualization (NFV) platform can support virtual network functions (VNFs) whose behavior can change during their lifecycles. For example, a VNF manager of the NFV platform can receive a request to update a condition of a VNF and/or an action to perform upon satisfaction of the condition. Based on the condition and action, the VNF manager can create or store a lifecycle management policy in an extensible lifecycle management model associated with the virtual network function. Based on the lifecycle management policy, the VNF manager can monitor the virtual network function to detect satisfaction of the condition and, in response to detecting satisfaction of the condition, the VNF manager can perform the action associated with the lifecycle management policy.

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

Abstract: A network function virtualization (NFV) platform can support hybrid and elastic scaling and recovery services. In one example, a system can deploy a cloud virtual network function manager (VNFM) and one or more cloud virtual network functions (VNFs) on a cloud. The system can monitor, via the cloud VNFM, a local VNFM on a local network, the cloud VNFM, and/or the one or more cloud VNFs. Based on the monitoring, the system can determine, via the cloud VNFM, a respective status of the local VNFM, the cloud VNFM, and/or the one or more cloud VNFs. Based on the respective status of the local VNFM, the cloud VNFM, and/or the one or more cloud VNFs, the system can then scale, via the cloud VNFM, the local VNFM, the cloud VNFM, and/or the one or more cloud VNFs.

Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

Abstract: The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.

Abstract: The present invention relates to novel substituted tetrahydropyran dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).